Hemangiol (Propranolol Hydrochloride)

Hemangiol is indicated for several clinical conditions where beta‑blockade provides therapeutic benefit, particularly in pediatric and adult populations. The medication is prescribed based on individual assessment and may be part of a broader treatment plan.

• Infantile hemangioma: oral propranolol reduces lesion growth and promotes involution in infants.
• Hypertension: lowers blood pressure by decreasing cardiac output and renin release.
• Cardiac arrhythmias: helps control supraventricular tachycardia and other rhythm disturbances.
• Migraine prophylaxis: may reduce frequency and severity of migraine attacks in selected patients.
• Off‑label vascular anomalies: sometimes used for other proliferative vascular lesions under specialist supervision.

Side effects of Hemangiol vary in frequency and severity; many patients experience mild symptoms while serious reactions are less common.

Common

• Fatigue or tiredness.
• Dizziness, especially when standing quickly.
• Cold extremities or reduced circulation to hands and feet.
• Gastrointestinal upset such as nausea or abdominal discomfort.
• Sleep disturbances or vivid dreams.
• Weight gain or increased appetite.

Serious

• Significant bradycardia or heart block.
• Severe hypotension leading to fainting.
• Bronchospasm or worsening asthma symptoms.

Before initiating Hemangiol, clinicians assess several factors to minimize risks and ensure safe use in each patient.

• Known hypersensitivity to propranolol or other beta‑blockers.
• History of asthma, chronic obstructive pulmonary disease, or other bronchospastic conditions.
• Pre‑existing bradycardia, heart block, or severe heart failure.
• Uncontrolled diabetes or severe peripheral vascular disease.
• Pregnancy, lactation, or plans for conception (use only if benefits outweigh risks).
• Concomitant use of other antihypertensive agents that may cause additive hypotension.

Hemangiol can interact with other medications; some combinations should be avoided while others require careful monitoring.

Avoid

• Non‑selective beta‑blockers or other agents that further lower heart rate or blood pressure.
• Calcium channel blockers such as verapamil that may cause severe bradycardia.
• Certain anti‑arrhythmic drugs (e.g., class I agents) that increase risk of conduction abnormalities.

Use with caution

• Antidiabetic drugs, as propranolol may mask hypoglycemia symptoms.
• Inhaled bronchodilators or corticosteroids in asthmatic patients.
• Antidepressants like SSRIs that can affect heart rate variability.